Rock Springs Capital INDV Position
Active3-Fund ConvergenceRock Springs Capital initiated a new position in Indivior Pharmaceuticals, Inc. (INDV) in Q4 2025, holding $3.8M worth of shares across 105,100 shares.
INDV is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals Inc is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.
Full company profile →Short Interest
9.8%
3.9 days to cover
Frequently Asked Questions
Does Rock Springs Capital own INDV?
Yes. As of Q4 2025, Rock Springs Capital holds 105,100 shares of Indivior Pharmaceuticals, Inc. (INDV) valued at $3.8M. This data comes from their SEC 13F filing.
How many hedge funds own INDV?
3 specialist biotech hedge funds currently hold INDV, including Deerfield Management, Driehaus Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Rock Springs Capital first buy INDV?
Rock Springs Capital's position in INDV was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Rock Springs Capital's INDV position increasing or decreasing?
Rock Springs Capital initiated a new position in INDV in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
INDVCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Rock Springs CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →